Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 506

Similar articles for PubMed (Select 19602900)

1.

Analytical review of the evidence for renoprotection by renin-angiotensin-aldosterone system blockade in chronic kidney disease - a call for caution.

Onuigbo MA.

Nephron Clin Pract. 2009;113(2):c63-9, discussion c70. doi: 10.1159/000228536. Epub 2009 Jul 14. Review.

2.

Current possibilities of ACE inhibitor and ARB combination in arterial hypertension and its complications.

Kolasinska-Malkowska K, Filipiak KJ, Gwizdala A, Tykarski A.

Expert Rev Cardiovasc Ther. 2008 Jun;6(5):759-71. doi: 10.1586/14779072.6.5.759. Review.

PMID:
18510491
3.
4.

Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?

Ong HT.

J Am Board Fam Med. 2009 Nov-Dec;22(6):686-97. doi: 10.3122/jabfm.2009.06.090094. Review.

6.

No impact of hyperkalaemia with renin-angiotensin system blockades in maintenance haemodialysis patients.

Han SW, Won YW, Yi JH, Kim HJ.

Nephrol Dial Transplant. 2007 Apr;22(4):1150-5. Epub 2007 Jan 25.

9.
10.

Optimal dose of angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker for renoprotection.

Hou FF, Zhou QG.

Nephrology (Carlton). 2010 Jun;15 Suppl 2:57-60. doi: 10.1111/j.1440-1797.2010.01315.x. Review.

PMID:
20586951
11.

Reducing cardiovascular risk by blockade of the renin-angiotensin-aldosterone system.

Cohn JN.

Adv Ther. 2007 Nov-Dec;24(6):1290-304. Review.

PMID:
18165212
13.

Choosing among renin-angiotensin system blockers for the management of hypertension: from pharmacology to clinical efficacy.

Neutel JM.

Curr Med Res Opin. 2010 Jan;26(1):213-22. doi: 10.1185/03007990903444434. Review.

PMID:
19921961
14.

Angiotensin receptor blockers in chronic renal disease: the promise of a bright clinical future.

Mackenzie HS, Ziai F, Omer SA, Nadim MK, Taal MW.

J Am Soc Nephrol. 1999 Apr;10 Suppl 12:S283-6. Review.

PMID:
10201884
15.

Blocking the renin-angiotensin system: dual- versus mono-therapy.

Ravandi A, Teo KK.

Expert Rev Cardiovasc Ther. 2009 Jun;7(6):667-74. doi: 10.1586/erc.09.47. Review.

PMID:
19505282
16.

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design.

Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Ghadanfar M, Weissbach N, Xiang Z, Armbrecht J, Pfeffer MA.

Nephrol Dial Transplant. 2009 May;24(5):1663-71. doi: 10.1093/ndt/gfn721. Epub 2009 Jan 14.

18.
19.

Angiotensin receptor blockers: RAAS blockade and renoprotection.

Ruilope LM.

Curr Med Res Opin. 2008 May;24(5):1285-93. doi: 10.1185/030079908X291921 . Epub 2008 Mar 25. Review.

PMID:
18366863
20.

Therapeutic approaches in lowering albuminuria: travels along the renin-angiotensin-aldosterone-system pathway.

Heerspink HJ.

Adv Chronic Kidney Dis. 2011 Jul;18(4):290-9. doi: 10.1053/j.ackd.2011.04.001. Review.

PMID:
21782135
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk